Terapia biológica em pacientes com artrite psoriásica com e sem experiência prévia no uso de medicamentos biológicos
DOI:
https://doi.org/10.11606/issn.2176-7262.rmrp.2022.192928Palavras-chave:
Artrite psoriásica, Inibidores do fator de necrose tumoral, Qualidade de vida, Efetividade, SegurançaResumo
Objetivo: avaliar os efeitos da terapia biológica sobre a atividade da doença, funcionalidade, qualidade de vida, persistência no tratamento e segurança em pacientes com artrite psoriásica sem experiência e com experiência prévia em terapia biológica. Métodos: um estudo observacional prospectivo de um ano foi realizado. Os desfechos avaliados foram a persistência no tratamento, atividade da doença, funcionalidade, qualidade de vida e segurança. Um modelo de regressão linear múltipla foi utilizado para avaliar os fatores preditores de resposta clínica. Resultados: foram incluídos 205 pacientes, dos quais 155 não tinham e 50 tinham experiência prévia com medicamentos biológicos. As taxas de persistência no tratamento foram maiores para pacientes sem experiência prévia em comparação aos experientes em seis meses de acompanhamento, mas não em 12 meses. As taxas de persistência no tratamento foram 71,5% em pacientes sem experiência prévia e 70% em pacientes com experiência prévia em 12 meses. Todos os desfechos clínicos avaliados melhoraram em ambos os grupos de pacientes. Aos 12 meses, 63% dos pacientes sem experiência prévia e 52% dos pacientes com experiência prévia apresentaram melhora na qualidade de vida. Além disso, 48% dos pacientes sem experiência prévia e 42% dos pacientes com experiência prévia apresentaram melhora na funcionalidade. A doença axial melhorou em 67% dos pacientes sem experiência prévia e em 56% dos pacientes com experiência prévia. Um bom controle da doença articular periférica foi observado em 49% dos pacientes sem experiência prévia e em 44% dos pacientes com experiência prévia. Os principais fatores preditores de pior resposta clínica foram sexo feminino, uso de etanercepte ou infliximabe, bem como pior funcionalidade e qualidade de vida no início do estudo. Conclusão: a saúde dos pacientes melhorou após o início do tratamento com os medicamentos biológicos. Em geral, pacientes com experiência prévia com medicamentos biológicos apresentaram mais reações adversas e menor efetividade.
Downloads
Referências
Haugeberg G, Michelsen B, Kavanaugh A. Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: A cross-sectional study of outpatient clinic patients in the biologic treatment era. RMD Open. 2020 May;6(1):e001223. doi: 10.1136/rmdopen-2020-001223.
Dures E, Hewlett S, Lord J, Bowen C, McHugh N; PROMPT Study Group, Tillett W. Important Treatment Outcomes for Patients with Psoriatic Arthritis: A Multisite Qualitative Study. Patient. 2017 Aug;10(4):455-462. doi: 10.1007/s40271-017-0221-4. Erratum in: Patient. 2019 Mar 23;:
Mease PJ. Biologic Therapy for Psoriatic Arthritis. Rheum Dis Clin North Am. 2015 Nov;41(4):723-38. doi: 10.1016/j.rdc.2015.07.010.
Caso F, Lubrano E, Del Puente A, Caso P, Peluso R, Foglia F, Benigno C, Girolimetto N, Bottiglieri P, Scarpa R, Costa L. Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2016;12(3):315-31. doi: 10.1586/1744666X.2016.1117941.
Alten R, Conaghan PG, Strand V, Sullivan E, Blackburn S, Tian H, Gandhi K, Jugl SM, Deodhar A. Unmet needs in psoriatic arthritis patients receiving immunomodulatory therapy: results from a large multinational real-world study. Clin Rheumatol. 2019 Jun;38(6):1615-1626. doi: 10.1007/s10067-019-04446-z.
Michelsen B, Diamantopoulos AP, Høiberg HK, Soldal DM, Kavanaugh A, Haugeberg G. Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population. J Rheumatol. 2017 Apr;44(4):431-436. doi: 10.3899/jrheum.160973.
da Silva MRR, Dos Santos JBR, Almeida AM, Kakehasi AM, de Oliveira Junior HA, Álvares-Teodoro J, Acurcio FA. Effectiveness and safety of anti-TNF in psoriatic arthritis patients in Brazil: a post-incorporation analysis. J Comp Eff Res. 2018 Oct;7(10):989-1000. doi: 10.2217/cer-2018-0017.
da Silva MRR, Dos Santos JBR, Almeida AM, Guerra Júnior AA, Alvares Teodoro J, Acurcio FA. Biological therapy in the treatment of psoriatic arthritis: economic and epidemiological considerations. Expert Rev Clin Immunol. 2019 Aug;15(8):879-887. doi: 10.1080/1744666X.2019.1631798.
Oelke KR, Chambenoit O, Majjhoo AQ, Gray S, Higgins K, Hur P. Persistence and adherence of biologics in US patients with psoriatic arthritis: analyses from a claims database. J Comp Eff Res. 2019 Jun;8(8):607-621. doi: 10.2217/cer-2019-0023.
Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, Primdahl J, McGonagle DG, Aletaha D, Balanescu A, Balint PV, Bertheussen H, Boehncke WH, Burmester GR, Canete JD, Damjanov NS, Kragstrup TW, Kvien TK, Landewé RBM, Lories RJU, Marzo-Ortega H, Poddubnyy D, Rodrigues Manica SA, Schett G, Veale DJ, Van den Bosch FE, van der Heijde D, Smolen JS. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):700-712. doi: 10.1136/annrheumdis-2020-217159.
Mease PJ, Karki C, Liu M, Li Y, Gershenson B, Feng H, Hur P, Greenberg JD. Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry. RMD Open. 2019 Apr 24;5(1):e000880. doi: 10.1136/rmdopen-2018-000880.
Zhang H, Wen J, Alexander GC, Curtis JR. Comparative effectiveness of biologics and targeted therapies for psoriatic arthritis. RMD Open. 2021 Apr;7(1):e001399. doi: 10.1136/rmdopen-2020-001399.
Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006 Aug;54(8):2665-73. doi: 10.1002/art.21972.
da Silva MRR, Dos Santos JBR, Almeida AM, Alvares-Teodoro J, Kakehasi AM, Acurcio FA. Access to high-cost medications for psoriatic arthritis in the National Health System in Brazil: the long path up to dispensation. Adv Rheumatol. 2019 Nov 14;59(1):48. doi: 10.1186/s42358-019-0091-7.
Orbai AM, Ogdie A. Patient-Reported Outcomes in Psoriatic Arthritis. Rheum Dis Clin North Am. 2016 May;42(2):265-83. doi: 10.1016/j.rdc.2016.01.002.
Acosta Felquer ML, Ferreyra Garrott L, Marin J, Catay E, Scolnik M, Scaglioni V, Ruta S, Rosa J, Soriano ER. Remission criteria and activity indices in psoriatic arthritis. Clin Rheumatol. 2014 Sep;33(9):1323-30. doi: 10.1007/s10067-014-2626-y.
Fernández-Sueiro JL, Willisch A, Pértega-Díaz S, Tasende JA, Fernández-López JC, Villar NO, Galdo F, Blanco FJ. Validity of the bath ankylosing spondylitis disease activity index for the evaluation of disease activity in axial psoriatic arthritis. Arthritis Care Res (Hoboken). 2010 Jan 15;62(1):78-85. doi: 10.1002/acr.20017.
Mease PJ, Woolley JM, Bitman B, Wang BC, Globe DR, Singh A. Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol. 2011 Nov;38(11):2461-5. doi: 10.3899/jrheum.110546.
Coretti S, Ruggeri M, McNamee P. The minimum clinically important difference for EQ-5D index: a critical review. Expert Rev Pharmacoecon Outcomes Res. 2014 Apr;14(2):221-33. doi: 10.1586/14737167.2014.894462.
Mongin D, Lauper K, Turesson C, Hetland ML, Klami Kristianslund E, Kvien TK, Santos MJ, Pavelka K, Iannone F, Finckh A, Courvoisier DS. Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique? RMD Open. 2019 Oct 17;5(2):e000994. doi: 10.1136/rmdopen-2019-000994.
Ribeiro da Silva MR, Ribeiro Dos Santos JB, Maciel Almeida A, Itria A, Maria Kakehasi A, Alvares Teodoro J, de Assis Acurcio F. Medication persistence for psoriatic arthritis in a Brazilian real-world setting. Future Sci OA. 2019 Jan 18;5(2):FSO369. doi: 10.4155/fsoa-2018-0101.
Costa L, Perricone C, Chimenti MS, Del Puente A, Caso P, Peluso R, Bottiglieri P, Scarpa R, Caso F. Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence. Drugs R D. 2017 Dec;17(4):509-522. doi: 10.1007/s40268-017-0215-7.
Glintborg B, Østergaard M, Dreyer L, Krogh NS, Tarp U, Hansen MS, Rifbjerg-Madsen S, Lorenzen T, Hetland ML. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum. 2011 Feb;63(2):382-90. doi: 10.1002/art.30117.
Aaltonen K, Heinonen A, Joensuu J, Parmanne P, Karjalainen A, Varjolahti-Lehtinen T, Uutela T, Puurtinen-Vilkki M, Arstila L, Blom M, Sokka T, Nordström D. Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: A prospective cohort study. Semin Arthritis Rheum. 2017 Jun;46(6):732-739. doi: 10.1016/j.semarthrit.2016.09.005.
Murage MJ, Tongbram V, Feldman SR, Malatestinic WN, Larmore CJ, Muram TM, Burge RT, Bay C, Johnson N, Clifford S, Araujo AB. Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. Patient Prefer Adherence. 2018 Aug 21;12:1483-1503. doi: 10.2147/PPA.S167508.
Vieira-Sousa E, Eusébio M, Ávila-Ribeiro P, Khmelinskii N, Cruz-Machado R, Rocha TM, Bernardes M, Santos-Faria D, Silva JL, Santos H, Miguel C, Carvalho P, Costa T, Duarte AC, Meirinhos T, Nero P, Fonseca JE, Santos MJ. Real-world Longterm Effectiveness of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis Patients from the Rheumatic Diseases Portuguese Register. J Rheumatol. 2020 May 1;47(5):690-700. doi: 10.3899/jrheum.181272.
Gladman DD, Thavaneswaran A, Chandran V, Cook RJ. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis. 2011 Dec;70(12):2152-4. doi: 10.1136/ard.2011.150938. Epub 2011 Sep 12. Erratum in: Ann Rheum Dis. 2012 Sep;71(9):1592.
Lemos LL, de Oliveira Costa J, Almeida AM, Junior HO, Barbosa MM, Kakehasi AM, Acurcio FA. Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety. Rheumatol Int. 2014 Oct;34(10):1345-60. doi: 10.1007/s00296-014-3006-2.
Harrold LR, Stolshek BS, Rebello S, Collier DH, Mutebi A, Wade SW, Malley W, Greenberg JD, Etzel CJ. Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry. Clin Rheumatol. 2017 Apr;36(4):895-901. doi: 10.1007/s10067-017-3593-x.
Ruyssen-Witrand A, Perry R, Watkins C, Braileanu G, Kumar G, Kiri S, Nott D, Liu-Leage S, Hartz S, Sapin C. Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. RMD Open. 2020 Feb;6(1):e001117. doi: 10.1136/rmdopen-2019-001117.
Atteno M, Peluso R, Costa L, Padula S, Iervolino S, Caso F, Sanduzzi A, Lubrano E, Del Puente A, Scarpa R. Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol. 2010 Apr;29(4):399-403. doi: 10.1007/s10067-009-1340-7.
Alves de Oliveira Junior H, Pereira da Veiga T, Acurcio FA, Almeida AM, Ribeiro Dos Santos JB, da Silva MRR, Kakehasi AM, Cherchiglia ML. Impact of biologic DMARDs on quality of life: 12-month results of a rheumatic diseases cohort using the Brazilian EQ-5D tariff. Hosp Pract (1995). 2020 Oct;48(4):213-222. doi: 10.1080/21548331.2020.1785212.
Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewé R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch FVD, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, van der Heijde D. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018 Jan;77(1):3-17. doi: 10.1136/annrheumdis-2017-211734. Epub 2017 Jul 6. Erratum in: Ann Rheum Dis. 2018 Mar;77(3):472.
Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014 Mar;74(4):423-41. doi: 10.1007/s40265-014-0191-y.
Moraes FA, da Silva MRR, Dos Santos JBR, Acurcio FA, Almeida AM, Kakehasi AM, Alvares-Teodoro J. Health-Related Quality of Life in Psoriatic Arthritis: Findings and Implications. Value Health Reg Issues. 2021 Aug 11;26:135-141. doi: 10.1016/j.vhri.2021.06.003.
Perrotta FM, Marchesoni A, Lubrano E. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs. J Rheumatol. 2016 Feb;43(2):350-5. doi: 10.3899/jrheum.150805.
Xu Y, Sudharshan L, Hsu MA, Koenig AS, Cappelleri JC, Liu WF, Smith TW, Pasquale MK. Patient Preferences Associated with Therapies for Psoriatic Arthritis: A Conjoint Analysis. Am Health Drug Benefits. 2018 Nov;11(8):408-417.
Merola JF, Lockshin B, Mody EA. Switching biologics in the treatment of psoriatic arthritis. Semin Arthritis Rheum. 2017 Aug;47(1):29-37. doi: 10.1016/j.semarthrit.2017.02.001.
Santin G, da Silva MMM, Villarreal VA, Laste LDD, de Freitas Montin E, Betiol LER, Azevedo VF. Home storage of biological medications administered to patients with rheumatic diseases. Adv Rheumatol. 2020 May 27;60(1):30. doi: 10.1186/s42358-020-00131-x.
da Silva MRR, Dos Santos JBR, Almeida AM, Alvares-Teodoro J, Acurcio FA. Economic evaluation of adalimumab versus etanercept for psoriatic arthritis in a Brazilian real-world model. Expert Rev Pharmacoecon Outcomes Res. 2021 Feb 9:1-7. doi: 10.1080/14737167.2021.1880325.
Dos Santos JBR, da Silva MRR, Almeida AM, Acurcio FA, Alvares-Teodoro J. Cost-utility analysis of the anti-TNF therapy for rheumatoid arthritis in a real-world based model. Expert Rev Pharmacoecon Outcomes Res. 2021 Oct;21(5):1011-1016. doi: 10.1080/14737167.2021.1840980.
Carneiro S, Palominos PE, Anti SMA, Assad RL, Gonçalves RSG, Chiereghin A, Lyrio AM, Ximenes AC, Saad CG, Gonçalves CR, Kohem CL, Marques CDL, Schainberg CG, de Souza Meirelles E, Resende GG, Pieruccetti LB, Keiserman MW, Yazbek MA, Sampaio-Barros PD, da Cruz Lage R, Bonfiglioli R, Oliveira TL, Azevedo VF, Bianchi WA, Bernardo WM, Dos Santos Simões R, de Medeiros Pinheiro M, Campanholo CB. Brazilian Society of Rheumatology 2020 guidelines for psoriatic arthritis. Adv Rheumatol. 2021 Nov 24;61(1):69. Doi: 10.1186/s42358-021-00219-y.
Brazil. Ministry of Health. Joint Ordinance No. 09, of May 21, 2021. Approves the Clinical Protocol and Therapeutic Guidelines for Psoriatic Arthritis. Available in: . Accessed on: December 22, 2021
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2022 Michael Ruberson Ribeiro da Silva, Jéssica Barreto Ribeiro dos Santos , Adriana Maria Kakehasi , Alessandra Maciel Almeida , Juliana Alvares-Teodoro Alvares-Teodoro, Francisco de Assis Acurcio
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Como Citar
Dados de financiamento
-
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Números do Financiamento 471819/2013-1 -
Fundação de Amparo à Pesquisa do Estado de Minas Gerais
Números do Financiamento PPM-0515-15 -
Fundação de Amparo à Pesquisa do Estado de Minas Gerais
Números do Financiamento 03799-16
